These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 2007317)

  • 1. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
    von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
    Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment.
    Daniel WA; Syrek M; Mach A; Wójcikowski J; Boksa J
    Pol J Pharmacol; 1997; 49(6):439-52. PubMed ID: 9566048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteers.
    Chakraborty BS; Hawes EM; McKay G; Hubbard JW; Korchinski ED; Midha KK; Choc MG; Robinson WT
    Drug Metabol Drug Interact; 1988; 6(3-4):425-37. PubMed ID: 3271648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption and excretion of thioridazine and mesoridazine in man.
    Charalampous KD; Johnson PC; Estevez V
    Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients.
    Dorado P; Berecz R; Peñas-Lledó EM; de la Rubia A; Llerena A
    Eur J Clin Pharmacol; 2007 May; 63(5):527-8. PubMed ID: 17345072
    [No Abstract]   [Full Text] [Related]  

  • 6. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
    Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
    J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioreceptor assay and high-performance liquid chromatography yield similar results for serum thioridazine and its major metabolites.
    Rao ML; Brown WA; Wagner R
    Ther Drug Monit; 1988; 10(2):184-7. PubMed ID: 3381236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
    Dahl-Puustinen ML; Lidén A; Alm C; Nordin C; Bertilsson L
    Clin Pharmacol Ther; 1989 Jul; 46(1):78-81. PubMed ID: 2743709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E; Steiner E; Ericsson O; Sjöqvist F
    Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat.
    Lin G; Hawes EM; McKay G; Korchinski ED; Midha KK
    Xenobiotica; 1993 Oct; 23(10):1059-74. PubMed ID: 8259689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot of plasma thioridazine and metabolites in chronically treated patients.
    Papadopoulos AS; Chand TG; Crammer JL; Lader S
    Br J Psychiatry; 1980 Jun; 136():591-6. PubMed ID: 7388266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenolic metabolites of thioridazine in man.
    Papadopoulos AS; Crammer JL; Cowan DA
    Xenobiotica; 1985 Apr; 15(4):309-16. PubMed ID: 4024665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
    Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism.
    Löf A; Hansen SH; Näslund P; Steiner E; Wallén M; Hjelm EW
    Clin Pharmacol Ther; 1990 Mar; 47(3):412-7. PubMed ID: 2311341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.
    LLerena A; Berecz R; de la Rubia A; Dorado P
    J Psychopharmacol; 2002 Dec; 16(4):361-4. PubMed ID: 12503836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators.
    Davi H; Bonnet JM; Berger Y
    Xenobiotica; 1992 Feb; 22(2):171-84. PubMed ID: 1632106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
    Steiner E; Spina E
    Clin Pharmacol Ther; 1987 Sep; 42(3):278-82. PubMed ID: 3621781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine.
    Eap CB; Souche A; Koeb L; Baumann P
    Ther Drug Monit; 1991 Jul; 13(4):356-62. PubMed ID: 1780970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.